文献速递肿瘤 PET/CT

68Ga-NOTA(68Ga-NGUL)与68Ga-PSMA-11在转移性前列腺癌中的头对头比较:一项前瞻性研究

Head-to-Head Comparison of 68Ga-NOTA (68Ga-NGUL) and 68Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study.
PubMed 文献 · J Nucl Med · 2021-02-26

该前瞻性研究纳入11例转移性前列腺癌患者,在同组患者中头对头比较新型PSMA示踪剂68Ga-NGUL与68Ga-PSMA-11的PET/CT表现。结果显示68Ga-NGUL正常器官摄取显著更低、尿液清除快,检出的PSMA阳性原发及转移病灶数量和部位一致,定量摄取无显著差异,但肿瘤/本底比值相对较低。

要点

  • 68Ga-NGUL正常器官摄取显著低于68Ga-PSMA-11,尿液清除快。
  • 两者检出的PSMA阳性原发和转移病灶数量与部位一致,定量摄取无显著差异。
  • 68Ga-NGUL肿瘤/本底比值相对低于68Ga-PSMA-11。

核心结论

  • 在与68Ga-PSMA-11的头对头比较中,68Ga-NGUL正常器官摄取更低,检测PSMA阳性原发和转移病灶的表现相似,可作为PSMA显像的可选示踪剂。

研究设计与样本

  • 前瞻性研究,纳入11例转移性前列腺癌患者,在同组患者中比较68Ga-NGUL与68Ga-PSMA-11的PET/CT表现。
  • 定量测定正常器官及原发和转移病灶的示踪剂摄取。

主要发现

  • 68Ga-NGUL正常器官摄取显著更低,并表现为快速尿液清除。
  • 68Ga-NGUL与68Ga-PSMA-11检出的PSMA阳性原发和转移病灶数量和部位一致,未观察到定量摄取显著差异。
  • 68Ga-NGUL的肿瘤/本底比值相对低于68Ga-PSMA-11。

临床怎么用

  • 68Ga-NGUL可作为PSMA PET/CT显像的可选示踪剂,尤其关注正常器官本底较低时。
  • 因肿瘤/本底比值相对较低,解读68Ga-NGUL图像时需结合病灶部位与临床信息综合判断。

局限性

  • 样本量仅11例转移性前列腺癌患者,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

68Ga-NOTA Glu-Urea-Lys (NGUL) is a novel prostate-specific membrane antigen (PSMA)-targeting tracer used for PET/CT imaging. This study aimed to compare performance in the detection of primary and metastatic lesions and to compare biodistribution between 68Ga-NGUL and 68Ga-PSMA-11 in the same patients with prostate cancer. Methods: Eleven patients with metastatic prostate cancer were prospectively recruited. The quantitative tracer uptake was determined in normal organs and in primary and metastatic lesions. Results:68Ga-NGUL showed significantly lower normal-organ uptake and rapid urinary clearance. The number and sites of detected PSMA-positive primary and metastatic lesions were identical, and no significant quantitative uptake difference was observed. 68Ga-NGUL showed a relatively lower tumor-to-background ratio than 68Ga-PSMA-11. Conclusion: In a head-to-head comparison with 68Ga-PSMA-11, 68Ga-NGUL showed lower uptake in normal organs and similar performance in detecting PSMA-avid primary and metastatic lesions. 68Ga-NGUL could be a valuable option for PSMA imaging.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Suh M, Im HJ, Ryoo HG, et al. Head-to-Head Comparison of 68Ga-NOTA (68Ga-NGUL) and 68Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study. J Nucl Med. 2021. PMID: 33637585. doi:10.2967/jnumed.120.258434

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。